ChiCTR2600123222 版本V1.0 版本创建时间2026/04/22 17:58:31 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123222 

最近更新日期:

Date of Last Refreshed on:

2026-04-22 17:58:15 

注册时间:

Date of Registration:

2026-04-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

探討線上睡眠和情緒治療課程在新冠病毒康復者中的效用

Public title:

Evaluation the effects of an online sleep and mood intervention in adults recovered from COVID-19

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探討線上睡眠和情緒治療課程在新冠病毒康復者中的效用

Scientific title:

Evaluation the effects of an online sleep and mood intervention in adults recovered from COVID-19

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

朱曉恩 

研究负责人:

陳銀燕博士 

Applicant:

Hiu Yin Chu 

Study leader:

Dr. CHAN Ngan Yin 

申请注册联系人电话:

Applicant telephone:

+852 3971 0548

研究负责人电话:

Study leader's telephone:

+852 3971 0548

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

alicechu@cuhk.edu.hk

研究负责人电子邮件:

Study leader's E-mail:

rachel.chan@cuhk.edu.hk

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

香港新界沙??鞍?亞公?33號沙?醫院7樓精神 科辦公室

研究负责人通讯地址:

香港新界沙??鞍?亞公?33號沙?醫院7樓精神 科辦公室

Applicant address:

7/F, Shatin Hospital, 33 A Kung Kok, Ma On Shan, Shatin, New Territories, Hong Kong

Study leader's address:

7/F, Shatin Hospital, 33 A Kung Kok, Ma On Shan, Shatin, New Territories, Hong Kong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

香港中??學精神科學系

Applicant's institution:

Department of Psychiatry, The Chinese University of Hong Kong

研究负责人所在单位:

香港中??學

Affiliation of the Leader:

The Chinese University of Hong Kong

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022.181

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

香港中??學 – 新界東醫院聯網臨床研究倫理聯席委員會

Name of the ethic committee:

Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2022-06-27 00:00:00

伦理委员会联系人:

Envy Lee

Contact Name of the ethic committee:

Envy Lee

伦理委员会联系地址:

香港沙?威爾斯親王醫院呂志和臨床醫學?樓8樓

Contact Address of the ethic committee:

8/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+852 3505 3935

伦理委员会联系人邮箱:

Contact email of the ethic committee:

crec@cuhk.edu.hk

研究实施负责(组长)单位:

香港中??學

Primary sponsor:

The Chinese University of Hong Kong

研究实施负责(组长)单位地址:

香港新界沙??鞍?亞公?33號沙?醫院7樓精神科辦公室

Primary sponsor's address:

7/F, Shatin Hospital, 33 A Kung Kok, Ma On Shan, Shatin, New Territories, Hong Kong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中國

省(直辖市):

香港特別政區

市(区县):

Country:

China

Province:

Hong Kong

City:

单位(医院):

香港中文大學

具体地址:

香港新界沙田馬鞍山亞公角亞公角街33號7樓精神科辦公室

Institution
hospital:

The Chinese University of Hong Kong

Address:

7/F, Shatin Hospital, 33 A Kung Kok, Ma On Shan, Shatin, New Territories, Hong Kong

经费或物资来源:

醫療衞生研究基金

Source(s) of funding:

HMRF - Research Fellowship Scheme

Target disease:

COVID-19

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究旨在透過數位心理健康平台,提供著重於睡眠及情緒的線上跨診斷心理介入,以減緩長期神經精神後遺症,並探索微生物組在數位化循證心理健康介入治療反應中的潛在角色。本研究假設:1)接受數位化跨診斷心理介入的受試者,在介入後其睡眠、情緒、生活品質及整體幸福感將有所改善;2)腸道微生物組可調節受試者對DMH介入的治療反應。  

Objectives of Study:

This project aims to provide online transdiagnostic intervention focusing sleep and mood to mitigate the long-term neuropsychiatric sequelae via Digital Mental Health (DMH) platform and also explore the potential role of microbiome for treatment response to digitally delivered evidence-based mental health intervention. We hypothesised that 1) Subjects who receive the digital-delivered transdiagnostic psychological interventions would have improved sleep, mood and quality of life and overall well-being after the intervention; and 2) The microbiota would moderate the treatment responses to the DMH intervention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

新冠康復者組:至少在三個月前曾感染新型冠狀病毒並康復 自評:病人健康狀況問卷-9(PHQ-9)≥ 10(抑鬱)、廣泛性焦慮量表-7(GAD-7)≥ 10(焦慮)、或失眠嚴重度量表(ISI)≥ 14(失眠) 達到臨床診斷標準:經微型國際神經精神訪談(MINI)及根據DSM-5標準的睡眠模式與障礙結構式診斷訪談(DISP)評估,符合抑鬱、焦慮或失眠障礙的診斷標準 非新冠對照組: 為確保兩組有相似的人口學狀況,納入年齡和性別配對、且精神心理困擾程度相近的無新冠感染人士作為對照組

Inclusion criteria

COVID-19 survivors and age- and sex-matched non-COVID controls: Self-reported: Patient Health Questionnaire-9 (PHQ-9) >= 10 (depression), Generalized Anxiety Disorder-7 (GAD-7) >= 10 (anxiety), or Insomnia Severity Index (ISI) >= 14 (insomnia) Meet clinical diagnostic criteria for depression, anxiety, or insomnia disorders, as assessed by the Mini-international Neuropsychiatric Interview (MINI) and Structured Diagnostic Interview for Sleep Patterns and Disorders (DISP) based on DSM-5 criteria Non-COVID Control Group: Age- and sex-matched controls with comparable psychiatric distress will be included for balanced demographics During the COVID pandemic, even non-COVID subjects may experience significant distress Controlling for distress level—through psychometric ratings and clinical diagnosis—enables better comparison of gut dysbiosis’ moderation effect on intervention

排除标准:

年齡未滿18歲

Exclusion criteria:

Age<18

研究实施时间:

Study execute time:

From 2022-06-27 00:00:00 To 2027-02-23 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-27 00:00:00 To 2023-02-23 00:00:00  

干预措施:

Interventions:

组别:

新冠康復者

样本量:

107

Group:

COVID-19 survivors

Sample size:

干预措施:

數位心理健康平台

干预措施代码:

Intervention:

Digital Mental Health (DMH) platform

Intervention code:

组别:

非新冠對照組

样本量:

107

Group:

Non-COVID Control

Sample size:

干预措施:

數位心理健康平台

干预措施代码:

Intervention:

Digital Mental Health (DMH) platform

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中國

省(直辖市):

香港特別行政區 

市(区县):

 

Country:

China 

Province:

Hong Kong (SAR) 

City:

 

单位(医院):

香港中文大學 

单位级别:

大學 

Institution
hospital:

The Chinese University of Hong Kong

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

失眠嚴重度量表

指标类型:

主要指标

Outcome:

Insomnia Severity Index

Type:

Primary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

病人健康狀況問卷-9

指标类型:

主要指标

Outcome:

Patient Health Questionnaire-9

Type:

Primary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

廣泛性焦慮量表-7

指标类型:

主要指标

Outcome:

General Anxiety Disorder-7 (GAD-7)

Type:

Primary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

臨床總體印象評估

指标类型:

主要指标

Outcome:

The Clinical Global Impressions Scale (CGI-I)

Type:

Primary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

腸道微生物

指标类型:

次要指标

Outcome:

Gut microbiota

Type:

Secondary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

艾和夫瞌睡評估表

指标类型:

次要指标

Outcome:

Epworth Sleepiness Scale

Type:

Secondary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

疲勞量表

指标类型:

次要指标

Outcome:

Chalder Fatigue Scale-11

Type:

Secondary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

指标中文名:

世界衞生組織生活質素問卷

指标类型:

次要指标

Outcome:

World Health Organization Quality-of-Life Scale

Type:

Secondary indicator

测量时间点:

基線、干預後、干預後6個月、干預後12個月、干預後24個月、干預後36個月及干預後48個月

测量方法:

Measure time point of outcome:

Baseline, post-intervention, at 6-month, 12-month, 24-month, 36-month and 48-month follow-up

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

大便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果发表之后的6个月内。原始數據可應合理要求提供,惟須連同研究計劃書一併提交予研究負責人联系索取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No more than six months following publication. Method of data access:Raw data may be obtained upon reasonable request, accompanied by a research proposal submitted to the principal investigator.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表, 電子採集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-22 17:58:15